15 assets in Marinesco-Sjogren Syndrome

Therapeutic assets addressing Marinesco-Sjogren Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Marinesco-Sjogren Syndrome	Sixth Affiliated Hospital, Sun Yat-sen University	P3	B (61)
Cetuximab Marinesco-Sjogren Syndrome	Sixth Affiliated Hospital, Sun Yat-sen University	P3	B (60)
Oxaliplatin Marinesco-Sjogren Syndrome	Sixth Affiliated Hospital, Sun Yat-sen University	P3	B (58)
Atezolizumab Marinesco-Sjogren Syndrome	Replimune, Inc.	P2	CCC (53)
Capecitabine Marinesco-Sjogren Syndrome	First Affiliated Hospital of Zhejiang University	P2	CCC (53)
Celecoxib Marinesco-Sjogren Syndrome	Sun Yat-sen University	P2	CCC (53)
Envafolimab Marinesco-Sjogren Syndrome	Beijing Hospital	P2	CCC (53)
Regorafenib Marinesco-Sjogren Syndrome	Sun Yat-sen University	P2	CCC (53)
rp2 Marinesco-Sjogren Syndrome	Replimune, Inc.	P2	CCC (53)
rp3 Marinesco-Sjogren Syndrome	Replimune, Inc.	P2	CCC (53)
Serplulimab Marinesco-Sjogren Syndrome	First Affiliated Hospital of Zhejiang University	P2	CCC (53)
Toripalimab Marinesco-Sjogren Syndrome	Sun Yat-sen University	P2	CCC (53)
atp128 Marinesco-Sjogren Syndrome	Amal Therapeutics	P1	CC (41)
Ezabenlimab Marinesco-Sjogren Syndrome	Amal Therapeutics	P1	CC (41)
Vsv-Gp128 Marinesco-Sjogren Syndrome	Amal Therapeutics	P1	CC (41)